Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 8/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5890712 | 0.95 | AVPR2 (0.48) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5890931 | 0.94 | AVPR2 (0.45) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5891147 | 0.93 | AVPR1A (0.42) | AVPR2ROCK2AVPR1A | |
| SCHEMBL5891337 | 0.92 | AVPR2 (0.44) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL6632264 | 0.91 | AVPR2 (0.52) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5891650 | 0.90 | AVPR2 (0.46) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5782632 | 0.89 | AVPR2 (0.50) | AVPR2ROCK2AVPR1APDE4APDE4B | |
| SCHEMBL5890845 | 0.88 | AVPR2 (0.46) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5890765 | 0.88 | AVPR2 (0.42) | AVPR2ROCK2ROCK1AVPR1APDE4A | |
| SCHEMBL5785906 | 0.88 | AVPR2 (0.49) | AVPR2ROCK2AVPR1APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | claimed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | claimed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2002083683-A9 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH CORP (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1377581-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | AVPR2 70/4885ROCK2 4797/4885ROCK1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.